{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:01:12Z","timestamp":1787320872195,"version":"build-2736575974"},"reference-count":63,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017727","name":"Fondazione Beretta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017727","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-breast-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.clbc.2024.04.003","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T12:33:21Z","timestamp":1712579601000},"page":"411-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis"],"prefix":"10.1016","volume":"24","author":[{"given":"Rebecca","family":"Pedersini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5999-6808","authenticated-orcid":false,"given":"Martina","family":"Buffoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Petrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ghidini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"di Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Amoroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Parati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Laini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Cosentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Schivardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clbc.2024.04.003_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.clbc.2024.04.003_bib0002","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"issue":"10200","key":"10.1016\/j.clbc.2024.04.003_bib0003","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet North Am Ed"},{"issue":"5","key":"10.1016\/j.clbc.2024.04.003_bib0004","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/CCO.0000000000000656","article-title":"Antibody-drug conjugates in breast cancer: the chemotherapy of the future?","volume":"32","author":"Nicol\u00f2","year":"2020","journal-title":"Curr Opin Oncol"},{"issue":"20","key":"10.1016\/j.clbc.2024.04.003_bib0005","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1158\/1078-0432.CCR-11-0762","article-title":"Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer","volume":"17","author":"LoRusso","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.clbc.2024.04.003_bib0006","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clbc.2024.04.003_bib0007","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1369\/0022155411410430","article-title":"Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target","volume":"59","author":"Stepan","year":"2011","journal-title":"J Histochem Cytochem"},{"issue":"3\u20134","key":"10.1016\/j.clbc.2024.04.003_bib0008","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/genesandcancer.40","article-title":"Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications","volume":"6","author":"Shvartsur","year":"2014","journal-title":"Genes Cancer"},{"issue":"10","key":"10.1016\/j.clbc.2024.04.003_bib0009","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.clbc.2024.04.003_bib0010","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.clbc.2024.04.003_bib0011","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clbc.2024.04.003_bib0012","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clbc.2024.04.003_bib0013","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.clbc.2024.04.003_bib0014","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1016\/j.clbc.2024.04.003_bib0015","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2024.04.003_bib0016","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clbc.2024.04.003_bib0017","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clbc.2024.04.003_bib0018","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","article-title":"Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer","volume":"35","author":"Bardia","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2024.04.003_bib0019","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.annonc.2020.09.004","article-title":"Sacituzumab govitecan in previously treated hormone receptor-positive\/HER2-negative metastatic breast cancer: final results from a phase I\/II, single-arm, basket trial","volume":"31","author":"Kalinsky","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2024.04.003_bib0020","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study","volume":"20","author":"Tamura","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2024.04.003_bib0021","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Invest New Drugs"},{"issue":"1","key":"10.1016\/j.clbc.2024.04.003_bib0022","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.clbc.2024.04.003_bib0023","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Syst Rev"},{"issue":"9","key":"10.1016\/j.clbc.2024.04.003_bib0024","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"7414","key":"10.1016\/j.clbc.2024.04.003_bib0025","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.clbc.2024.04.003_bib0026","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a Rank Correlation Test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"issue":"7109","key":"10.1016\/j.clbc.2024.04.003_bib0027","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.clbc.2024.04.003_bib0028","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1358\/dot.2019.55.9.3039669","article-title":"Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors","volume":"55","author":"Fenn","year":"2019","journal-title":"Drugs Today (Barc)"},{"issue":"1","key":"10.1016\/j.clbc.2024.04.003_bib0029","doi-asserted-by":"crossref","first-page":"23262","DOI":"10.1038\/srep23262","article-title":"Safety and efficacy of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer: a meta-analysis","volume":"6","author":"Shen","year":"2016","journal-title":"Sci Rep"},{"issue":"17","key":"10.1016\/j.clbc.2024.04.003_bib0030","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"44","key":"10.1016\/j.clbc.2024.04.003_bib0031","doi-asserted-by":"crossref","first-page":"e22886","DOI":"10.1097\/MD.0000000000022886","article-title":"A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy","volume":"99","author":"Ji","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.clbc.2024.04.003_bib0032","doi-asserted-by":"crossref","first-page":"493","DOI":"10.21873\/invivo.11088","article-title":"Safety evaluation of trastuzumab emtansine in japanese patients with HER2-positive advanced breast cancer","volume":"31","author":"Watanabe","year":"2017","journal-title":"Vivo"},{"key":"10.1016\/j.clbc.2024.04.003_bib0033","article-title":"T-DM1 efficacy in patients with HER2-positive metastatic breast cancer progressing after a taxane plus pertuzumab and trastuzumab: an Italian multicenter observational study","author":"Conte","year":"2019","journal-title":"Clin Breast Cancer"},{"issue":"8","key":"10.1016\/j.clbc.2024.04.003_bib0034","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.04.003_bib0035","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2018.12.022","article-title":"Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1","volume":"109","author":"Montemurro","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2024.04.003_bib0036","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","article-title":"Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study","volume":"35","author":"Perez","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10390","key":"10.1016\/j.clbc.2024.04.003_bib0037","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.clbc.2024.04.003_bib0038","series-title":"Linee guida TERAPIA ANTIEMETICA National Guidelines system. Rome","year":"2020"},{"key":"10.1016\/j.clbc.2024.04.003_bib0039","volume":"1","year":"2024","journal-title":"NCCN Clinical Practice Guidelines in Oncology Antiemesis"},{"key":"10.1016\/j.clbc.2024.04.003_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102500","article-title":"The evolving therapeutic landscape of trastuzumab-drug conjugates: future perspectives beyond HER2-positive breast cancer","volume":"113","author":"Von Arx","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.clbc.2024.04.003_bib0041","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1007\/s00520-015-2750-5","article-title":"Impact and management of chemotherapy\/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists\/oncology nurses and patients: a cross-sectional multinational survey","volume":"23","author":"Vidall","year":"2015","journal-title":"Support Care Cancer"},{"issue":"11","key":"10.1016\/j.clbc.2024.04.003_bib0042","first-page":"1103","article-title":"Expert opinion on biological therapy","volume":"23","author":"Schlam","year":"2023","journal-title":"Manag Adverse Events Sacituzumab Govitecan"},{"key":"10.1016\/j.clbc.2024.04.003_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102672","article-title":"Breaking barriers in triple negative breast cancer (TNBC)\u2014unleashing the power of antibody-drug conjugates (ADCs)","volume":"123","author":"Dri","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clbc.2024.04.003_bib0044","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejca.2022.10.003","article-title":"Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer","volume":"178","author":"Loibl","year":"2023","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2024.04.003_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.clbc.2024.04.003_bib0046","doi-asserted-by":"crossref","first-page":"806","DOI":"10.2174\/1568009622666220513094352","article-title":"Netupitant-palonosetron (NEPA) for preventing chemotherapy-induced nausea and vomiting: from clinical trials to daily practice","volume":"22","author":"Aapro","year":"2022","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.clbc.2024.04.003_bib0047","unstructured":"Food and Drug Administration, Highliths of presbribing information: fam-trastuzumab deruxtecan-nxki for injection, for intravenous use. 2022. Reference ID: 4732117 Available on: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761139s024lbl.pdf."},{"issue":"11","key":"10.1016\/j.clbc.2024.04.003_bib0048","first-page":"CD012775","article-title":"Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis","volume":"11","author":"Piechotta","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.clbc.2024.04.003_bib0049","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","article-title":"A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy","volume":"25","author":"Aapro","year":"2014","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.clbc.2024.04.003_bib0050","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s40265-021-01558-2","article-title":"Netupitant\/palonosetron: a review in chemotherapy-induced nausea and vomiting","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.clbc.2024.04.003_bib0051","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations","volume":"62","author":"D'Arienzo","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"3","key":"10.1016\/j.clbc.2024.04.003_bib0052","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.1996.14.3.709","article-title":"Irinotecan is an active agent in untreated patients with metastatic colorectal cancer","volume":"14","author":"Conti","year":"1996","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clbc.2024.04.003_bib0053","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1200\/JCO.1995.13.6.1303","article-title":"Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study","volume":"13","author":"Leichman","year":"1995","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clbc.2024.04.003_bib0054","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Pirotta N Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer","volume":"343","author":"Saltz","year":"2000","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.clbc.2024.04.003_bib0055","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/jnci\/87.24.1876","article-title":"Irinotecan CPT-11 and characteristic mucosal changes in the mouse ileum and cecum","volume":"87","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2024.04.003_bib0056","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1998.16.8.2745","article-title":"Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment","author":"Saliba","year":"1998","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2024.04.003_bib0057","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clbc.2024.04.003_bib0058","doi-asserted-by":"crossref","first-page":"iv126","DOI":"10.1093\/annonc\/mdy145","article-title":"Diarrhoea in adult cancer patients: ESMO clinical practice guidelines","volume":"29","author":"Bossi","year":"2018","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clbc.2024.04.003_bib0059","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jpainsymman.2004.06.013","article-title":"Constipation management in palliative care: a survey of practices in the United Kingdom","volume":"29","author":"Goodman","year":"2005","journal-title":"J Pain Symptom Manage"},{"issue":"7","key":"10.1016\/j.clbc.2024.04.003_bib0060","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1177\/0269216308096908","article-title":"The management of constipation in palliative care: clinical practice recommendations","volume":"22","author":"Larkin","year":"2008","journal-title":"Palliat Med"},{"issue":"2","key":"10.1016\/j.clbc.2024.04.003_bib0061","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/01.SMJ.0000109215.54052.D8","article-title":"Incidence of constipation associated with long-acting opioid therapy: a comparative study","volume":"97","author":"Staats","year":"2004","journal-title":"South Med J"},{"issue":"4","key":"10.1016\/j.clbc.2024.04.003_bib0062","doi-asserted-by":"crossref","first-page":"iv111","DOI":"10.1093\/annonc\/mdy148","article-title":"ESMO guidelines committee. Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines","volume":"29","author":"Larkin","year":"2018","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2024.04.003_bib0063","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924001034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924001034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T10:54:10Z","timestamp":1718880850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820924001034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1526820924001034"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2024.04.003","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2024.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}